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Herpes simplex virus (HSV) glycoprotein B (gB) is one of the four viral glycoproteins required for viral entry and cell fusion and is highly
conserved among herpesviruses. Mutants of HSV type 2 gB were generated by substituting conserved residues in the cytoplasmic tail with alanine
or by deleting 41 amino acids from the C-terminus. Some of the mutations abolished cell fusion activity and also prevented transport of gB to the
cell surface, identifying residues in the gB cytoplasmic tail that are critical for intracellular transport of this glycoprotein. These mutations also
prevented production of infectious virus, possibly because the mutant forms of gB were not transported to the site of envelopment. Other
mutations, particularly the deletion, significantly enhanced cell fusion activity. These mutations, as well as others described previously, identify
regions of the gB cytoplasmic domain that modulate cell fusion activity.
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Membrane fusion is required for herpes simplex virus
(HSV) entry into cells as well as for virus induced cell–cell
fusion (reviewed by Spear, 1993). Both entry and cell fusion
require the functions of four viral glycoproteins. Glycopro-
teins B, D, H and L (gB, gD and heterodimers of gH/gL)
must all be present in the virion or expressed on the cells that
induce cell fusion and a gD receptor must be expressed on the
targeted cells. There are four known gD receptors (reviewed
by Spear et al., 2000), including herpesvirus entry mediator
(HVEM), a member of the tumor necrosis factor receptor
family; nectin-1 and nectin-2, members of the immunoglob-
ulin superfamily; and cell surface heparan sulfate modified by
specific 3-O-sulfotransferases. HVEM may function in the
regulation of immune responses through its cellular ligands
BTLA and LIGHT (Gonzalez et al., 2005; Granger and
Rickert, 2003; Sedy et al., 2005). The nectins are cell0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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other junctions in various cell types (Irie et al., 2004).
HSV-infected cells usually do not fuse with uninfected
neighboring cells, probably because the required viral
glycoproteins are targeted to the trans-Golgi-network (TGN)
or endosomes, where the final envelopment of nucleocapsids
occurs (reviewed by Mettenleiter, 2002). This targeting of
HSV glycoproteins depends on the expression of other HSV
proteins such as gM with UL49A and gK with UL20
(Avitabile et al., 2004; Crump et al., 2004). As discussed
below, gB has its own trafficking motifs which ensure
localization largely, but not entirely, to the TGN or
endosomes, due in part to recycling from the cell surface.
Mutations in gK, UL20, UL24 or the cytoplasmic tail of gB
can cause the syncytial phenotype (reviewed by Spear, 1993),
presumably because these mutations permit the HSV glyco-
proteins required for cell fusion to move more freely to the
cell surface.
Transfection of plasmids expressing HSV gB, gD, gH and
gL into effector cells is sufficient to induce fusion with target
cells expressing HSV entry receptors (Muggeridge, 2000;
Pertel et al., 2001; Turner et al., 1998). This cell fusion
occurs at neutral pH. Co-expression of gM/UL49A or gK/
UL20 not only redistributes the fusogenic HSV glycoproteins6) 229 – 237
www.e
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also inhibits HSV glycoprotein-induced cell fusion (Avitabile
et al., 2004; Crump et al., 2004; Klupp et al., 2000).
Mutations in the gB tail can cause the syncytial phenotype
after virus infection, and can also enhance or abolish the
fusion activity of transfected cells (Fig 1). Deletions from the
C-terminus of either HSV type 1 or 2 (HSV-1 or HSV-2) gB
had variable effects depending on the number of amino acids
deleted. Either there was no effect on gB cell surface
expression and cell fusion after transfection (last 9–10 amino
acids deleted) or there was enhancement of cell surface
expression and cell fusion (deletions encompassing the
downstream YXXA or LL motifs) or inhibition of cell
surface expression and cell fusion activity (deletions of 48 or
more amino acids) (Beitia Ortiz de Zarate et al., 2004; Fan et
al., 2002; Heineman et al., 2004). The inhibitory deletions
have been proposed to eliminate a putative endoplasmic
reticulum (ER) export signal (Beitia Ortiz de Zarate et al.,
2004; Heineman et al., 2004) (Fig. 1) or to result in gB
misfolding (Fan et al., 2002). Amino acid substitutions in the
gB tails of both HSV-1 and HSV-2 gB have been shown to
enhance cell fusion after transfection and/or to cause the
syncytial plaque phenotype (citations in legend to Fig. 1). In
most cases, these substitutions do not affect known or
postulated trafficking motifs and there is as yet no explana-
tion for their effects.
Alterations in the cytoplasmic tails of class I fusion
glycoproteins specified by other viruses have been shown to
modulate membrane-fusing activity by affecting conformation
and/or function of the ectodomains. For example, a C-
terminally truncated form of HIV gp41 exhibited an increased
rate of folding from a late prebundle conformation into a 6-
helix bundle and an increased rate of fusion (Abrahamyan et
al., 2005). Also, paramyxovirus strains differ in the lengths of
the cytoplasmic tails of the F glycoprotein. A strain with a
long tail was less syncytial than others, but truncation of the
tail greatly enhanced the ability of this strain to induce
syncytia (Tong et al., 2002). Moreover, addition of a domain
(one capable of inducing 3-helix bundle formation) to the C-Fig. 1. Mutations in gB that enhance HSV-induced or HSV-glycoprotein-induced c
HSV-2(333) gBs were aligned. Identities are indicated by double dots between the lin
or .) placed, above or below the lines of sequence, at the position of the last amino
function or cell fusion activity, larger deletions (b) resulted in significantly enhanced
Amino acid substitutions are indicated above or below the lines of sequence. Substi
substitutions with this phenotype are linked by lines). Substitutions in lower case lett
Zarate et al. (2004), Bzik et al. (1984), Diakidi-Kosta et al. (2003), Engel et al. (19
(2004), Muggeridge (2000), Muggeridge et al. (2004) and Walev et al. (1994).terminal cytoplasmic tail of a very fusogenic form of the F
protein reduced its fusogenicity by increasing the energy
required for the induction of membrane fusion (Waning et al.,
2004).
The HSV glycoprotein(s) most directly responsible for
membrane fusion has not yet been identified. It seems likely
that gD provides the trigger for the activation of membrane-
fusing activity, through its interaction with a cell receptor, but
that it is not the actual fusogen. This supposition is based in
part on findings that soluble or lipid-anchored gD can
substitute for authentic membrane-bound gD in inducing
membrane fusion (Cocchi et al., 2004; Jones and Geraghty,
2004). HSV gB, which is probably present in virions and
membranes as a homotrimer, and gH/gL, present as hetero-
dimers, are both candidates for fusion proteins (Gianni et al.,
2005a, 2005b; Okazaki and Kida, 2004). No one has yet
reported conditions under which either HSV gB or gH–gL is
dispensable for viral entry or cell fusion, however.
Among herpesviruses, gB is the most highly conserved
of the three glycoproteins that are universally required for
viral entry and cell fusion, gB, gH and gL. The purpose of
this study was to mutate conserved amino acids in the
cytoplasmic tail of HSV gB in order to investigate further
the role of gB in inducing or modulating membrane fusion,
as assessed by cell fusion and viral entry. We identified 2
membrane-proximal mutations that significantly enhanced
cell fusion activity, but not viral entry, and others that had
some enhancing activity or were without effect. We also
identified 4 membrane-proximal mutations and 2 down-
stream mutations, only one affecting a putative trafficking
motif, that inhibited transport of gB to the cell surface and
also inhibited cell fusion and production of infectious virus.
Thus, the absence of cell fusion can be attributed to
absence of gB at the cell surface. The mutants with
enhanced cell fusion activity identify gB tail residues that
are probably critical for interactions with cell proteins or for
intrachain or interchain interactions of gB monomers
responsible for the modulation of cell fusion activity but
not viral entry.ell fusion. Amino acid sequences of the cytoplasmic tails of HSV-1(KOS) and
es of sequence. Deletions from the C-terminus are indicated by symbols (˝, b,
acid in each truncated mutant. The smallest deletions (.) had no effect on gB
cell fusion activity, and the largest deletions (˝) eliminated cell fusion activity.
tutions in upper case letters were shown to enhance cell fusion activity (double
ers had no effect on cell fusion activity. Summarized from data in Beitia Ortiz de
93), Fan et al. (2002), Foster et al. (2001), Gage et al. (1993), Heineman et al.
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Conserved regions of the cytoplasmic tail of gB and mutations
generated
Alignment of amino acids in the cytoplasmic tails of gBs
encoded by a variety of alphaherpesviruses revealed the
existence of two highly conserved regions (Fig. 2). Five
amino acid residues, marked with asterisks in Fig. 2, are
conserved in alphaherpesviruses whose natural hosts are
animals as diverse as turtles, chickens, pigs and humans.
Four of these five residues are also conserved in some
betaherpesviruses. Most of the amino acid substitutions
characterized to date in HSV-1 gB (gB1) or HSV-2 gB
(gB2) were found in mutants identified by their syncytial
plaque morphology (Fig. 1). Few, if any, studies have been
designed to identify cytoplasmic tail residues that are
essential for gB function and less is known about the
effects of amino acid substitutions in the gB2 tail than in
the gB1 tail. Therefore, we generated a number of Ala
substitution mutations targeted to several of the more highly
conserved residues in gB2, as shown in Fig. 2. The mutants
are named for the amino acid substituted and the position of
the amino acid in the mature protein, numbering from the
first amino acid after signal peptidase cleavage (for example,
L776). For purposes of comparison with other truncation
mutations, we also generated mutant gBD41, which is
missing the last 41 amino acids from the C-terminus of
gB2.Fig. 2. Conservation of regions in the cytoplasmic tails of alphaherpesvirus gBs a
from the cytoplasmic tails of gBs encoded by HSV-2 (VGBEB2), HSV-1 (VGBEK
VGBEC6), equine herpesvirus 4 (EHV-4, VGBEQH), pseudorabies virus (PRV,
(MDV, VGBERB), green turtle lung–eye– trachea-associated disease virus (LET
parentheses are given the virus name abbreviations used in this figure and the Ge
pairwise global alignments of all sequences and progressive assembly of alignment
of the 10-gB tails; residues identical in all 10 are indicated by asterisks below the a
counting from the first amino acid after the signal peptidase cleavage site. Ala sub
alignment. These substitutions either enhanced cell fusion activity (bold-faced A), h
indicates the last amino acid in the truncation mutant gBD41.Effects of the gB2 mutations on cell surface expression
Two kinds of experiments were done to assess effects of the
gB2 mutations on cell surface expression levels: CELISA on
gB2-transfected CHO cells and immunofluorescence on trans-
fected BHK-95-19 cells, the cells to be used as effectors in the
cell fusion assay. For CELISA, the CHO cells were transfected
with plasmids expressing wild-type or mutant forms of gB2,
washed and incubated with a polyclonal anti-gB rabbit serum,
washed and fixed and then incubated with an anti-rabbit
detection system. Several of the gB2 tail mutants (L776,
M781, L784, P786, M824, L830 and E835) exhibited low
levels of, or no detectable, presentation at the cell surface in
comparison with wild-type gB2 (Fig. 3). Five of the Ala
substitution mutants (P780, Y785, D814, V831, and R860)
were detected on cell surfaces at levels 50%–110% that of wild-
type gB2 control levels. The truncation mutant gBD41 was
presented on the cell surface at levels 150% that of wild-type
gB2 (data not shown).
The second type of experiment, indirect immunofluores-
cence microscopy, demonstrated that all the gB2 mutants
retained epitopes recognized by the anti-gB rabbit serum and
that the CELISA results, for the most part, identified those
mutants capable of being transported to the cell surface.
Transfected BHK-95-19 cells were fixed and permeabilized
with methanol before anti-gB primary antibody was bound, or
were incubated with the same primary antibody at 37 -C
before fixation. The latter condition permits the live cells to
take up the antibodies by endocytosis, provided there is cellnd positions of Ala substitutions. The sequences selected for alignment were
1), bovine herpesvirus 2 (BHV-2, VGBEBH), equine herpesvirus 1 (EHV-1,
VGBEPS), bovine herpesvirus 1 (BHV-1, VGBEBC), Marek’s disease virus
V, AAM95776), and infectious laryngotracheitis virus (ILTV, VGBEIS). In
nBank protein database accession numbers. The alignment was performed by
s using Neighbor-Joining phylogeny. Shaded residues are identical in at least 6
lignment. Residue numbers given above the alignment are for HSV-2 gB only,
stitutions were introduced into HSV-2 gB at the positions indicated above the
ad little or no effect (A) or abrogated cell fusion activity (a). The symbol (b)
Fig. 3. Cell surface expression and cell fusion activities of the gB2 Ala
substitution mutants. Results for cell surface expression of the gB2 mutants, as
determined by CELISA and expressed as a percentage of wild-type gB2
expression levels, are represented by the hatched bars. CHO-K1 cells were
transfected with wild-type or mutant gB2-expressing plasmids or empty vector
control plasmid and, after 48 h, were incubated with an anti-gB rabbit serum.
The cells were then washed, fixed and incubated with a rabbit antibody
detection system. The solid black bars present results for the cell fusion assay,
with activity for the gB2 mutants expressed as a percentage of activity observed
with wild-type gB2. BHK-95-19 cells were transfected with plasmids
expressing gD2, gH2, gL2 and T7 polymerase, along with a plasmid expressing
the wild type or mutant forms of gB2 or an empty vector control plasmid
(effector cells). CHO-K1 cells were transfected with a plasmid carrying the
luciferase gene under control of the T7 promoter and a plasmid expressing the
entry/fusion receptor, nectin-1 (target cells). At 6 h after transfection, the 2 cell
populations were mixed in 96-well dishes and incubated for an additional 18 h.
The cells were then lysed and expression of luciferase was quantified by use of
the luciferase assay kit (Promega). In three independent CELISA experiments,
each done in triplicate, mean OD380 values indicative of gB2 cell surface
expression ranged from 0.70 to 0.95 for wild-type gB2 and from 0.16 to 0.26
for the empty vector controls. In three independent cell fusion experiments,
each done in triplicate, mean luciferase activity in arbitrary units ranged from
574 to 10550 for wild-type gB2 and from 10 to 620 for the empty vector
controls. The control values were subtracted from test values before calculation
of means within each experiment and calculation of percentages (mutant gB2
values expressed as a percentage of wild-type gB2 values). The values
presented represent the means of percentages calculated for the three
independent experiments with standard deviations.
Fig. 4. Binding of anti-gB antibodies to live and fixed BHK-95-19 cells
transfected with wild-type or mutant forms of gB2. BHK-95-19 cells were
transfected with plasmids expressing wild-type gB2 or each of the gB2 mutants
indicated. For assessment of gB2 presentation on the surfaces of live cells, the
transfected cells were washed, blocked with normal goat serum, and incubated
with an anti-gB rabbit serum at 37 -C for 30 min, during which time some
endocytosis of gB-bound antibodies occurred. The cells were then washed
fixed in methanol, and incubated with Alexa 568-conjugated goat anti-rabbi
IgG. For intracellular staining, the cells were washed, fixed with methanol
blocked and incubated with the primary and secondary antibodies jus
described. Photographs were taken with a Zeiss LSM510 confocal microscope
using a 100 objective. The up or down arrows indicate whether the mutations
enhanced or inhibited cell fusion, respectively.
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Zarate et al., 2004). Fig. 4 shows that neither endocytosed
primary antibodies nor primary antibodies bound to the cell
surface were detected on cells exposed to the antibodies
before fixation for certain gB2 mutants (P786 or L830),
indicating absence of cell surface expression of gB2. Similar
results were obtained for mutants not shown (L776, M781,
L784, M824). All other mutants resembled wild-type gB2
(Fig. 4) with respect to cell surface expression, as assessed by
detection of anti-gB antibodies bound to, or endocytosed by,
live cells. Specific intracellular staining was observed for all
the gB2 mutants when the anti-gB antibodies were added to
the fixed and permeabilized cells. These results and those
obtained by CELISA indicate that severely reduced levels of
cell surface expression were evident only for mutants L776,
M781, L784, P786, M824 and L830. Mutant E835 was




Fig. 5. Presence of fusion-competent forms of gB in filopodia-like extensions
from the cell periphery. HeLa cells were transfected with plasmids expressing
wild-type or mutant forms of gB2 and processed 18 h later. The cells were
washed, fixed in ice-cold methanol, blocked with normal goat serum and
incubated with anti-gB rabbit serum, followed by secondary antibodies Alexa
488-conjugated goat anti-rabbit IgG. Photographs were taken as described in
the legend to Fig. 4. Some of the fluorescent images were over-exposed to
enable visualization of filopodia-like cellular extensions containing gB (marked
with thick arrows). The up or down arrows beside the mutant name indicate
whether the mutations enhanced or inhibited cell fusion, respectively.
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in Fig. 4) even though the CELISA results showed severely
reduced levels of anti-gB bound to cell surfaces. A possible
explanation is that, while mutant E835 can be transported to
the cell surface and recycled from the cell surface by
endocytosis of antigen–antibody complexes, the dwell time
on the cell surface may be short. Alternatively, mutant E835
may behave differently in the CHO cells used for CELISA
than in the BHK-95-19 cells used for immunofluorescence.
Immunofluorescence results for gBD41, similarly to
CELISA results, showed high levels of surface expression,
particularly on cellular protrusions. We noted that presence of
gB on filopodia-like protrusions was characteristic for all forms
of gB (wild-type and mutant) capable of inducing cell fusion
but not for the fusion-incompetent mutants (Fig. 5).
Effects of the gB2 mutations on cell fusion activity
Cell fusion assays were performed as described (Pertel et al.,
2001) except that the effector cells were BHK-95-19 cells
transfected with a mixture of plasmids expressing gB2 (wild-
type or mutant), gD2, gH2, gL2 and T7 polymerase. The target
cells were CHO cells transfected with a plasmid expressing
nectin-1 as a fusion receptor and a plasmid carrying the
luciferase gene under control of the T7 promoter. We used
BHK-95-19 cells as effectors because these mutant cells, in
contrast to CHO cells, are devoid of entry/fusion receptors for
HSV-2 (Roller and Herold, 1997), thus preventing the fusion of
cells with each other within the effector cell population. When
effector cells fuse with target cells, luciferase is produced and
can be quantitated as a measure of cell fusion.
As shown in Fig 3, the twelve Ala substitution mutants fell
into 3 categories. Some of these Ala substitutions significantly
enhanced the cell fusion activity of gB2 (P780, Y785 and, to a
lesser extent, D814 and V831), others had little or no effect
(E835 and R860) and the remainder severely reduced cell
fusion activity (L776, M781, L784, P786, M824 and L830).
The C-terminal truncation mutant gBD41 was 7 times more
active than wild-type gB2 in inducing cell fusion (data not
shown). The enhanced levels of cell fusion activity did not
necessarily correlate with enhanced levels of gB2 cell surface
expression, as was previously noted with other gB2 mutants
(Fan et al., 2002). Mutants P780 and Y785 exhibited enhanced
cell fusion activity despite somewhat reduced cell surface
expression. Although mutant gBD41 was 7 times more active
than wild-type gB2 in cell fusion activity, the levels of cell
surface expression were enhanced by only 50%. Finally,
mutant E835 exhibited significantly reduced cell surface
expression (in CHO cells) but was indistinguishable from
wild-type gB2 in cell fusion activity, using BHK-95-19 cells as
the glycoprotein-expressing effector cells.
Point mutations in the tail of gB that can abrogate cell fusion
activity have not previously been described. Six of the mutants
described here (L776, M781, L784, P786, M824 and L830)
were significantly impaired for cell fusion activity and were
also significantly impaired for transport to the cell surface.
Thus, effects of these mutations on intracellular trafficking ofgB2 can explain the loss of cell fusion activity. Two of these
Ala substitutions are located in the membrane-proximal region
of the tail adjacent to the Ala substitutions that caused greatest
enhancement in cell fusion activity (Fig. 2). It was interesting
to note, for example, that mutant Y785 was transported to the
cell surface and was highly active in cell fusion whereas the
adjacent mutations (L784 and P786) abrogated transport to the
cell surface and cell fusion activity. The mutations that
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undiscovered determinants of gB2 folding or intracellular
trafficking.
Effects of the gB2 mutations on virion infectivity
HSV-1(KOS)K082 is a gB-null mutant resulting from
insertion of a stop codon near the N-terminus of the gB open
reading frame (Cai et al., 1987). This mutant is propagated in
complementing cells expressing gB, such as Vero-B24 cells
that were stably transfected with the gene for gB1. The
homologous gBs of HSV-1 and HSV-2 can be exchanged in
complemented viruses with good recovery of infectivity (Fan et
al., 2002). Viruses complemented with either wild-type or
mutant forms of gB2 were obtained by passing the mutant virus
once through Vero cells transfected with plasmids expressing
either wild-type gB2 or one of the gB2 mutants. Titers of the
complemented viruses were determined by plaque assay on
monolayers of the Vero-B24 cells.
Fig. 6 presents the titers of infectious virus obtained from
the Vero cells expressing wild-type gB2 or one of the gB2
mutants. All but one of the gB2 mutants that were functional
in cell fusion also permitted generation of infectious virus by
complementation. Mutant E835 was the exception, having no
detectable ability to permit production of complemented
infectious virus. Possibly, this mutant cannot be incorporatedFig. 6. Ability of the gB2 mutants to confer entry activity on a gB-null HSV-1
mutant virus. Vero cells were transfected with plasmids expressing wild-type
gB2 or the gB2 mutants indicated or with an empty vector control plasmid. The
transfected cells were then inoculated with the gB-null mutant, HSV-
1(KOS)K082, which had been propagated in cells expressing wild-type gB1.
Unpenetrated virus was inactivated by low pH treatment of the cells and, after
allowing 24 h of incubation for viral replication, cell lysates were prepared for
titration of infectious progeny by plaque assay on Vero-B24 cells, which
provide wild-type gB1 to permit plaque formation. The values presented are
means of values from three independent experiments, with standard deviations.
The upper dotted line marks the value for wild-type gB2 and the lower dotted
line for the vector control. For purposes of relating these results to those
presented in Fig. 3, black bars identify the mutants with cell fusion activity
indistinguishable from that of wild-type gB2, white bars identify the mutants
with enhanced cell fusion activity, striped bars identify the mutants with greatly
reduced or no cell fusion activity, and the dotted bar is for the vector control.into virions or is functional at the cell surface for cell fusion
but not in virions. The mutants that had the highest levels of
cell fusion activity, gBD41, P780 and Y785, did not exhibit
enhanced levels of complementation but actually had some-
what reduced levels of complementation, a finding consistent
with previous reports (Fan et al., 2002; Muggeridge, 2000).
Mutant R860 was indistinguishable from wild-type gB2 for
complementation as well as for cell surface expression and
cell fusion activity. All gB2 mutants that were inactive in cell
fusion; L776, M781, L784, P786, M824 and L830, were also
inactive in complementation (infectious virus produced was
no more than that obtained using the empty vector, except for
the low level observed with mutant L776). The infectious
virus produced by Vero cells transfected with the empty
vector can be accounted for by revertants present in the K082
virus stock (recombination between the viral genome and gB1
gene occurs during propagation of the virus in Vero-B24
cells). Interestingly, mutant L830 caused the yields of
infectious virus to be 10-to 100-fold lower than those
obtained with empty vector, suggesting that this mutant had
a dominant negative effect on infectivity of the revertants
present in the virus stock.
Discussion
By targeting Ala substitution mutations to conserved
residues in the cytoplasmic tail of gB2, we have identified
residues that are critical for transport of gB to the cell surface.
Failure of these gB2 mutants to mediate cell fusion and to
complement the infectivity of a gB-null HSV mutant is most
likely explained by this altered trafficking. We have also
identified four previously undescribed amino acid substitu-
tions that can enhance cell fusion activity without significant
effects on the levels of gB2 cell surface expression. In
addition, we have confirmed results of others (Fan et al.,
2002) about the effects of deletions from the C-terminus of
gB2. We found that deletion of 41 amino acids enhanced cell
fusion activity greater than 7-fold, as well as enhanced cell
surface expression by about 50%, probably due to deletion of
endocytosis motifs. For some mutants, particularly deletion
mutants, higher levels of cell surface expression of gB2 may
explain in part the higher levels of cell fusion activity. This
explanation does not apply for most of the more fusogenic
point mutants, however, because their cell surface expression
was not increased, although cell surface distribution of the
mutated gB2 could be altered. Lack of a strict correlation
between enhancement of cell fusion activity of gB2 mutants
and levels of cell surface expression has been noted
previously (Fan et al., 2002).
The Ala substitutions that significantly reduced cell fusion
activity and complementation of viral infectivity were located
in two regions of the gB2 tail, interspersed with mutations
that enhanced cell fusion (Fig. 2). These inhibitory mutations
prevented efficient transport of gB2 from the site of synthesis
in the ER to the cell surface. This probably accounts entirely
for the absence of cell fusion and complementation activity.
Cell fusion presumably cannot occur without at least transient
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gB2 into virions cannot occur unless this glycoprotein is
transported to the site of secondary envelopment in the TGN
or endosomes (Mettenleiter, 2002). The six substitutions that
impaired intracellular trafficking of gB2 are outside of regions
thought to be important for gB oligomerization (Ali, 1990;
Navarro et al., 1993) and, except for L830, do not affect the
putative ER export motif shown in Fig. 1. Presumably, these
mutations identify residues critical for interaction of gB with
the export machinery or, alternatively, alter gB folding
resulting in retention of the misfolded protein in the ER.
The Ala substitutions in gB2 that enhanced cell fusion
activity were in a membrane-proximal region that is predicted
to be in a looped or extended conformation and a region in
the middle of the cytoplasmic tail that is predicted to form an
a-helix (Foster et al., 2001; Pellett et al., 1985). Mutation
E835A is in the latter region. Although E835A did not
enhance cell fusion activity, in comparison with wild-type
gB2, its low level of cell surface expression in CHO cells
suggests that this mutation might actually enhance the
fusogenic activity of gB2 at the same time that it reduces
cell surface expression. In other words, the specific fusogenic
activity of E835A could be higher than that of wild-type gB.
It should be noted that another substitution at this position in
gB2, E835D, was shown to enhance the cell fusion activity of
transfected cells and to cause the syncytial phenotype in HSV
infection (Muggeridge, 2000). It remains to be determined
how substitutions at E835, and the other substitutions and
deletion that enhanced cell fusion activity, influence intramo-
lecular interactions within the gB2 tail, interchain interactions
within the gB2 oligomer or intermolecular interactions with
cytoplasmic factors that could have a role in modulating cell
fusion activity.
Immunofluorescence studies revealed that gBD41 was
prominently displayed in cellular extensions or filopodia that
made contact with neighboring cells. This phenomenon was
also observed for wild-type gB2 and the mutants capable of
inducing cell fusion but not for the fusion-incompetent gB2
mutants (Fig. 5). This free movement of gB into filopodia
was not dependent on the expression of any of the other HSV
glycoproteins. It will be interesting to determine whether the
other HSV glycoproteins required for cell fusion co-migrate
with gB into filopodia and whether these membranous
protusions have a role in the induction of cell fusion.
HSV and other enveloped viruses have multiple means of
controlling membrane fusion and its timing, which controls
are necessary for efficient viral replication and spread of
infection. Cell fusion activity may be influenced in part by
whether the relevant glycoproteins can be transported to cell
contact sites, as regulated by intrinsic trafficking motifs or
viral and cellular traffic control proteins. In addition,
cytoplasmic tails of fusion proteins may, through intrinsic
features of the cytoplasmic domain or interactions with
cytoplasmic proteins, influence conformational changes and
function of the ectodomain. The phenotypes of the gB2
mutants described here exemplify both kinds of controls on
cell fusion activity.Materials and methods
Cells and viruses
Cell lines used included Chinese hamster ovary (CHO-K1)
cells (American Type Culture Collection); a mutant baby
hamster kidney cell line (BHK-95-19) that lacks HSV-1 or
HSV-2 entry and fusion receptors (Roller and Herold, 1997);
Vero cells; a Vero cell line carrying the gB1 gene (Vero-B24
cells) and used for titration and propagation of gB-null viruses
(Herold et al., 1991); and HeLa cells (American Type Culture
Collection). The CHO cell line was grown in Ham’s F12
medium supplemented with 10% fetal bovine serum (FBS).
The other cell lines were grown in DMEM supplemented with
10% FBS. HSV-1(KOS)K082 virus, an insertion mutant
capable of expressing only the first 43 amino acids of gB1
including the 30-amino acid signal sequence (Cai et al., 1987),
was obtained from S. Person (Pennsylvania State University)
and propagated in the complementing Vero-B24 cells.
Plasmids
Plasmids pCAGT7 and pT7EMCLuc express the T7
polymerase and carry the luciferase gene under control of the
T7 promoter (Okuma et al., 1999), respectively, and were
provided by Y. Matsuura (National Institute of Infectious
Diseases, Tokyo, Japan). Plasmids pAZB2, pAZD2, pAZH2
and pAZL2 express HSV-2(333) gB2, gD2, gH2, and gL2,
respectively, and were generated by insertion of the viral
glycoprotein open reading frames into pCAGGS (Zago and
Spear, 2003). Plasmid pAZB2D41, which expresses a truncated
form of gB2, was obtained similarly, using a reverse primer
that added a stop codon in place of 41 amino acids at the C-
terminus. To generate the point mutations described here, a
SacI fragment from pAZB2 was subcloned in pUC19. This
plasmid, which contains the C-terminal domain of gB2, served
as template for Ala substitution mutagenesis, using the
QuikChange Site-Directed Mutagenesis Kit (Strategene). The
mutagenized inserts were sequenced to ensure presence of the
correct mutations only and then ligated to the larger fragment
from SacI digests of pAZB2, to restore the gB2 open reading
frame in mutated form. The Ala substitutions were targeted to
12 residues, on the basis of the alignment shown in Fig. 2 and
identification of conserved residues in alphaherpesvirus gB
tails. The plasmids expressing the mutated forms of gB2 are
named pNR798E (L776A), pNR142 (P780A), pNR145
(M781A), pNR147 (L784A), pNR807RR (Y785A), pNR150
(P786A), pNR152 (D814A), pNR155 (M824A), pNR852ee
(L830A), pNR158 (V831A), pNR160 (E835A) and pNR162
(R860A).
Cell ELISA (CELISA)
To assess expression of gB2 on cell surfaces, a CELISAwas
performed as described previously (Geraghty et al., 2000).
Briefly, CHO-K1 cells were transfected with one of the gB2-
expressing plasmids described above, using Lipofectamine
N. Ruel et al. / Virology 346 (2006) 229–237236Reagent (Invitrogen) as recommended by the manufacturer. At
6 h after transfection, the cells were replated into 96-well
plates. At 42 h after replating, the cells were incubated for 30
min at room temperature with the rabbit polyclonal anti-gB
serum, R74 (Herold et al., 1994), at a 1:300 dilution in
phosphate-buffered saline (PBS) containing 3% bovine serum
albumin (BSA). The cells were then fixed with PBS containing
2% formaldehyde and 0.2% gluteraldehyde, and incubated
sequentially with biotinylated anti-rabbit IgG (Sigma), Amdex
streptavidin-conjugated horseradish peroxidase (HRP, Amer-
sham Pharmacia), and HRP substrate (BioFx Lab, Owings
Mills, MD). HRP product was quantified at 380 nm in a Victor
Wallac spectrophotometer (PerkinElmer).
Cell fusion assay
The cell fusion assay was performed as previously described
(Pertel et al., 2001) with some modifications. BHK-95-19 cells
were transfected with the HSV-2 set of plasmids expressing 3
of the glycoproteins required for cell fusion (gD2, gH2, and
gL2), along with a plasmid expressing either the wild type or a
mutant form of gB2 or an empty vector control, and a plasmid
expressing T7 RNA polymerase. CHO-K1 cells were trans-
fected with a plasmid carrying the firefly luciferase gene under
control of the T7 promoter (pT7ELCLuc) and plasmid pBG38
expressing nectin-1 (Geraghty et al., 1998). For transfection 0.4
Ag of each plasmid was added per well in a 6-well plate using
Lipofectamine reagent for CHO cells or Lipofectamine
Reagent and Plus Reagent (Invitrogen) for BHK-95-19 cells.
The total amount of plasmid DNA added per well was 2.0 Ag,
including empty vector pCAGGS, if necessary. At 6 h after
transfection, the 2 cell populations were trypsinized and
replated in 96 well plates (8.3  103 cells per well for CHO-
K1 and 2.6  103 cells per well for BHK-95-19). After an
additional 18 h, the cells were lysed and expression of
luciferase was quantified using the luciferase assay kit
(Promega) with readout on a Victor Wallac luminometer
(Perkin-Elmer).
Complementation of a gB-null virus for viral entry
Vero cells were transfected with plasmids expressing wild-
type or mutant forms of gB2 using Lipofectamine reagent.
After 12 h, the cells were infected at 4 pfu/cell with the
complemented gB-negative virus, HSV-1(KOS)K082. After 2
h, the virus inocula were removed and residual unpenetrated
virus was inactivated by exposure of the cells to 0.1 M citrate
buffer (pH 3.0) for 1 min. The cells were washed and incubated
in growth medium for 24 h. To prepare virus stocks, the cells
were washed with PBS, harvested and sonicated in 1 ml of
medium. Quantification of infectious virus yields was per-
formed by plaque assay on confluent 6-well plates of Vero-B24
cells, which were inoculated with serial dilutions of the viral
stocks (1 ml per well) for 2 h, and then incubated in growth
media supplemented with methylcellulose for 48 h. To
visualize plaques, an immunoassay was performed (Holland
et al., 1983). After washing the cells and fixation with PBScontaining 0.5% glutaraldehyde, the cells were treated with
permeabilizing solution (2 mM magnesium chloride, 0.01%
sodium deoxycholate, 0.02% NP40), blocked with PBS
containing 2% BSA and incubated sequentially with the anti-
gD monoclonal antibody III-174 (Para et al., 1985) at 1:200
dilution, biotinylated anti-mouse IgG (Sigma), streptavidin-
coupled h-galactosidase (Calbiochem), and the h-galactosidase
substrate 5-bromo-4-chloro-3-indolyl-h-d-galactopyranoside
(X-Gal; 0.5 mg/ml; GibcoBRL). Plaques were visualized as
blue foci. The plaques of 3 wells plated at 2 different virus
dilutions were counted. These raw scores were averaged and
titers were calculated. Means were determined from 3
independent experiments.
Indirect immunofluorescence and microscopy
For immunofluorescence of fixed and permeabilized cells,
HeLa or BHK-95-19 cells were transfected for 18 h with
plasmids expressing either the wild-type or a mutant form of
gB2 and washed with complete PBS, prior to a10-min fixation
in ice-cold methanol. Cells were washed with PBS, blocked
with normal goat serum for 5 min at 37 -C and again washed
before addition of primary antibody (anti-gB rabbit polyclonal
antiserum R74) for 30 min at 37 -C. The secondary antibodies
were Alexa 568- or Alexa 488-conjugated goat anti-rabbit
(Molecular Probes). To detect the binding of anti-gB antibodies
to live cell surfaces and subsequent uptake of the antibodies,
BHK-95-19 were incubated for 30 min at 37 -C with the anti-
gB rabbit polyclonal antiserum R74 and then washed and fixed
as described above. The secondary antibody used was Alexa
568-conjugated goat anti-rabbit. A Zeiss LSM510 confocal
microscope equipped with a 100, 1.4 NA oil immersion lens
was used for microscopy and photography.
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